Are you a US biotech company aiming to introduce your rare disease treatment to the French market? Our case study reveals the strategic steps and innovative solutions that can accelerate your drug's availability and establish a strong market presence.

Discover key insights on:

• How a US biopharmaceutical company can successfully launch an Early Access Program (EAP) in France with early reimbursement. ​

• The streamlined process to set up a French-compliant commercial subsidiary without immediate full local recruitment.

• ​Effective strategies to navigate regulatory, operational, and financial challenges. ​

• The role of AzurBio in expediting the EAP launch and reducing the standard timeline for establishing a local compliant commercial subsidiary by 18 months. ​ ​